MicroRNA involvement in hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) is the third cause of cancer‐related death worldwide. Curative options for HCC are limited and exclusively available for patients carrying an early stage HCC. In advanced stages, traditional chemotherapy proved to be only marginally effective or even toxic. Thus, the identification of new treatment options is needed. New targets for non‐conventional treatment will necessarily take advantage of progresses on the molecular pathogenesis of HCC. MicroRNAs (miRNAs) are a group of tiny RNAs with a fundamental role in the regulation of gene expression. Aberrant expression of several miRNAs was found to be involved in human hepatocarcinogenesis. miRNA expression signatures were correlated with bio‐pathological and clinical features of HCC. In some cases, aberrantly expressed miRNAs could be linked to cancer‐associated pathways, indicating a direct role in liver tumourigenesis. For example, up‐regulation of mir‐221 and mir‐21 could promote cell cycle progression, reduce cell death and favour angiogenesis and invasion. These findings suggest that miRNAs could become novel molecular targets for HCC treatment. The demonstration of in vivo efficacy and safety of anti‐miRNA compounds has opened the way to their use in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas
Kutay, H., Bai, S., Datta, J., Motiwala, T., Pogribny, I., Frankel, W., Jacob, S. T., & Ghoshal, K. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20982 · Cited by 608
RetractedDatta, J., Kutay, H., Nasser, M. W., Nuovo, G. J., Wang, B., Majumder, S., Liu, C.-G., Volinia, S., Croce, C. M., Schmittgen, T. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6655 · Cited by 438
Self-citationRetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationMicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Self-citationMazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
Self-citationSilencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 1×
“Either cholesterol-bound oligonucleotides (antagomirs), or LNA-modified oligonucleotides (LNA anti-miR) were also found to be effective in stably suppressing miRNA activity in the in vivo condition [156, 157].”
BackgroundRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656
miR-15 and miR-16 induce apoptosis by targeting BCL2
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506654102 · Cited by 3,517
Self-citationUnique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023 · cited 1×
“Since miR-210 is also up-regulated in HCC [97] as well as in a variety of solid cancers [135–138], its prognostic value may possibly be relevant for other cancers too, including HCC.”
BackgroundSelf-citationMicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557
Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0637 · Cited by 2,354
Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., & Ohnishi, K. (1985) · Cancer · doi:10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e · Cited by 1,931
let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells
Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y., Hu, X., Su, F., Lieberman, J., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.054 · Cited by 1,910
Asangani, I. A., Rasheed, S. A. K., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., & Allgayer, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210856 · Cited by 1,882
Si, M.-L., Zhu, S., Wu, H., Lu, Z., Wu, F., & Mo, Y.-Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210083 · Cited by 1,600
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 1×
“Either cholesterol-bound oligonucleotides (antagomirs), or LNA-modified oligonucleotides (LNA anti-miR) were also found to be effective in stably suppressing miRNA activity in the in vivo condition [156, 157].”
BackgroundLiu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,536
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
Bressac, B., Kew, M., Wands, J., & Ozturk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,432
MicroRNA Signatures in Human Ovarian Cancer
Iorio, M. V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., Taccioli, C., Volinia, S., Liu, C.-G., Alder, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1936 · Cited by 1,394
Self-citationA Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors
Voorhoeve, P. M., le Sage, C., Schrier, M., Gillis, A. J. M., Stoop, H., Nagel, R., Liu, Y.-P., van Duijse, J., Drost, J., Griekspoor, A., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.037 · Cited by 1,264
The role of microRNA genes in papillary thyroid carcinoma
He, H., Jazdzewski, K., Li, W., Liyanarachchi, S., Nagy, R., Volinia, S., Calin, G. A., Liu, C.-G., Franssila, K., Suster, S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509603102 · Cited by 1,215
Self-citationThe tumor suppressor microRNA let-7 represses the HMGA2 oncogene
Lee, Y. S., & Dutta, A. (2007) · Genes & Development · doi:10.1101/gad.1540407 · Cited by 1,152
Murakami, Y., Yasuda, T., Saigo, K., Urashima, T., Toyoda, H., Okanoue, T., & Shimotohno, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209283 · Cited by 1,147
Frankel, L. B., Christoffersen, N. R., Jacobsen, A., Lindow, M., Krogh, A., & Lund, A. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707224200 · Cited by 1,141 · cited 1×
“miR-21 can also down-regulate the tumour suppressor programmed cell death 4 (Pdcd4) [98, 99].”
BackgroundRNA interference targeting Fas protects mice from fulminant hepatitis
Song, E., Lee, S.-K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., & Lieberman, J. (2003) · Nature Medicine · doi:10.1038/nm828 · Cited by 1,110
Disrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic Transformation
Mayr, C., Hemann, M. T., & Bartel, D. P. (2007) · Science · doi:10.1126/science.1137999 · Cited by 1,100
Extensive modulation of a set of microRNAs in primary glioblastoma
Ciafrè, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C.-G., Sabatino, G., Negrini, M., Maira, G., Croce, C. M., & Farace, M. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.030 · Cited by 1,096 · cited 1×
“MiR-221, which was recently shown to be induced by MYCN [88] and repressed by p53 [89], emerged as a significantly up-regulated miRNA in glioblastoma, pancreatic, hepatocellular, kidney, bladder, prostate and thyroid cancer [44–46, 73, 79, 90–94], thus suggesting an oncogenic role in several human neoplasms.”
BackgroundSelf-citationMicroRNA-21 Targets the Tumor Suppressor Gene Tropomyosin 1 (TPM1)
Zhu, S., Si, M.-L., Wu, H., & Mo, Y.-Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611393200 · Cited by 1,090
A MicroRNA Signature of Hypoxia
Kulshreshtha, R., Ferracin, M., Wojcik, S. E., Garzon, R., Alder, H., Agosto-Perez, F. J., Davuluri, R., Liu, C.-G., Croce, C. M., Negrini, M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01395-06 · Cited by 1,055 · cited 1×
“Recently, up-regulation of miR-210, one of the miRNA that is induced under hypoxia [133],”
BackgroundSelf-citationMeng, F., Henson, R., Lang, M., Wehbe, H., Maheshwari, S., Mendell, J. T., Jiang, J., Schmittgen, T. D., & Patel, T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.057 · Cited by 984
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis
Huang, Q., Gumireddy, K., Schrier, M., le Sage, C., Nagel, R., Nair, S., Egan, D. A., Li, A., Huang, G., Klein-Szanto, A. J., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1681 · Cited by 975
Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., et al. (2000) · Nature Genetics · doi:10.1038/73448 · Cited by 960
Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., Menssen, A., Meister, G., & Hermeking, H. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4436 · Cited by 923
MicroRNA Expression Profiling in Prostate Cancer
Porkka, K. P., Pfeiffer, M. J., Waltering, K. K., Vessella, R. L., Tammela, T. L. J., & Visakorpi, T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0533 · Cited by 899
Ye, Q.-H., Qin, L.-X., Forgues, M., He, P., Kim, J. W., Peng, A. C., Simon, R., Li, Y., Robles, A. I., Chen, Y., et al. (2003) · Nature Medicine · doi:10.1038/nm843 · Cited by 850
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation
le Sage, C., Nagel, R., Egan, D. A., Schrier, M., Mesman, E., Mangiola, A., Anile, C., Maira, G., Mercatelli, N., Ciafrè, S. A., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601790 · Cited by 815
Gramantieri, L., Ferracin, M., Fornari, F., Veronese, A., Sabbioni, S., Liu, C.-G., Calin, G. A., Giovannini, C., Ferrazzi, E., Grazi, G. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4607 · Cited by 813
Self-citationZucman-Rossi, J., Jeannot, E., Van Nhieu, J. T., Scoazec, J.-Y., Guettier, C., Rebouissou, S., Bacq, Y., Leteurtre, E., Paradis, V., Michalak, S., et al. (2006) · Hepatology · doi:10.1002/hep.21068 · Cited by 760
Galardi, S., Mercatelli, N., Giorda, E., Massalini, S., Frajese, G. V., Ciafre, S. A., & Farace, M. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701805200 · Cited by 749
MicroRNA Expression Profiles in Serous Ovarian Carcinoma
Nam, E. J., Yoon, H., Kim, S. W., Kim, H., Kim, Y. T., Kim, J. H., Kim, J. W., & Kim, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1731 · Cited by 740
Identification of metastasis-related microRNAs in hepatocellular carcinoma
Budhu, A., Jia, H.-L., Forgues, M., Liu, C.-G., Goldstein, D., Lam, A., Zanetti, K. A., Ye, Q.-H., Qin, L.-X., Croce, C. M., et al. (2008) · Hepatology · doi:10.1002/hep.22160 · Cited by 697
Self-citationLadeiro, Y., Couchy, G., Balabaud, C., Bioulac-Sage, P., Pelletier, L., Rebouissou, S., & Zucman-Rossi, J. (2008) · Hepatology · doi:10.1002/hep.22256 · Cited by 684
hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer
Camps, C., Buffa, F. M., Colella, S., Moore, J., Sotiriou, C., Sheldon, H., Harris, A. L., Gleadle, J. M., & Ragoussis, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1755 · Cited by 662
Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b
Scott, G. K., Goga, A., Bhaumik, D., Berger, C. E., Sullivan, C. S., & Benz, C. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609383200 · Cited by 646
Anoikis resistance and tumor metastasis
Simpson, C. D., Anyiwe, K., & Schimmer, A. D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.05.029 · Cited by 644
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma
Fornari, F., Gramantieri, L., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G. A., Grazi, G. L., Giovannini, C., Croce, C. M., Bolondi, L., et al. (2008) · Oncogene · doi:10.1038/onc.2008.178 · Cited by 639
Self-citationlet-7 MicroRNA Functions as a Potential Growth Suppressor in Human Colon Cancer Cells
Akao, Y., Nakagawa, Y., & Naoe, T. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.903 · Cited by 619
let-7 microRNAs in development, stem cells and cancer
Büssing, I., Slack, F. J., & Großhans, H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.07.001 · Cited by 607
Okabe, H., Satoh, S., Kato, T., Kitahara, O., Yanagawa, R., Yamaoka, Y., Tsunoda, T., Furukawa, Y., & Nakamura, Y. (2001) · PubMed · Cited by 603
Micro-RNA profiling in kidney and bladder cancers
Gottardo, F., Liu, C. G., Ferracin, M., Calin, G. A., Fassan, M., Bassi, P., Sevignani, C., Byrne, D., Negrini, M., Pagano, F., et al. (2007) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.01.019 · Cited by 600
Self-citationSangiovanni, A., Del Ninno, E., Fasani, P., De Fazio, C., Ronchi, G., Romeo, R., Morabito, A., de Franchis, R., & Colombo, M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.049 · Cited by 600
Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin
Ding, Q., Xia, W., Liu, J.-C., Yang, J.-Y., Lee, D.-F., Xia, J., Bartholomeusz, G., Li, Y., Pan, Y., Li, Z., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.009 · Cited by 597 · cited 1×
“A stabilization of -catenin may also result from Erk-primed inactivation of GSK-3 or the action of HBV-X protein [29].”
BackgroundLeung, T. W. T., Tang, A. M. Y., Zee, B., Lau, W. Y., Lai, P. B. S., Leung, K. L., Lau, J. T. F., Yu, S. C. H., & Johnson, P. J. (2002) · Cancer · doi:10.1002/cncr.10384 · Cited by 583
MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic Utility
Nikiforova, M. N., Tseng, G. C., Steward, D., Diorio, D., & Nikiforov, Y. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2696 · Cited by 582
Laurent–Puig, P., Legoix, P., Bluteau, O., Belghiti, J., Franco, D., Binot, F., Monges, G., Thomas, G., Bioulac–Sage, P., & Zucman–Rossi, J. (2001) · Gastroenterology · doi:10.1053/gast.2001.24798 · Cited by 582
Focus on hepatocellular carcinoma
Bruix, J., Boix, L., Sala, M., & Llovet, J. M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00058-3 · Cited by 570
MicroRNA deregulation in human thyroid papillary carcinomas
Pallante, P., Visone, R., Ferracin, M., Ferraro, A., Berlingieri, M. T., Troncone, G., Chiappetta, G., Liu, C. G., Santoro, M., Negrini, M., et al. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01209 · Cited by 527
Self-citation(2000) · Hepatology · doi:10.1053/he.2000.5628 · Cited by 521
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma
Chevret, S., Trinchet, J.-C., Mathieu, D., Rached, A. A., Beaugrand, M., & Chastang, C. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80173-1 · Cited by 512
Jiang, J., Gusev, Y., Aderca, I., Mettler, T. A., Nagorney, D. M., Brackett, D. J., Roberts, L. R., & Schmittgen, T. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0523 · Cited by 511
Iizuka, N., Oka, M., Yamada-Okabe, H., Nishida, M., Maeda, Y., Mori, N., Takao, T., Tamesa, T., Tangoku, A., Tabuchi, H., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12775-4 · Cited by 511
Cyclin G is a transcriptional target of the p53 tumor suppressor protein.
Okamoto, K., & Beach, D. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06807.x · Cited by 455 · cited 1×
“Cyclin G1 was initially identified as a transcriptional target of p53 [101–104].”
BackgroundBarbara, L., Benzi, G., Gaiani, S., Fusconi, F., Zironi, G., Siringo, S., Rigamonti, A., Barbara, C., Grigioni, W., Mazziotti, A., et al. (1992) · Hepatology · doi:10.1002/hep.1840160122 · Cited by 431
Self-citationMicroRNA gene expression profile of hepatitis C virus–associated hepatocellular carcinoma†‡
Varnholt, H., Drebber, U., Schulze, F., Wedemeyer, I., Schirmacher, P., Dienes, H., & Odenthal, M. (2008) · Hepatology · doi:10.1002/hep.22158 · Cited by 431
Wong, Q. W. –., Lung, R. W. –., Law, P. T. –., Lai, P. B. –., Chan, K. Y. –., To, K., & Wong, N. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.003 · Cited by 424
Kaposi-Novak, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27236 · Cited by 398
Caspase 8 small interfering RNA prevents acute liver failure in mice
Zender, L., Hütker, S., Liedtke, C., Tillmann, H. L., Zender, S., Mundt, B., Waltemathe, M., Gösling, T., Flemming, P., Malek, N. P., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1330920100 · Cited by 384
Xu, X.-R., Huang, J., Xu, Z.-G., Qian, B.-Z., Zhu, Z.-D., Yan, Q., Cai, T., Zhang, X., Xiao, H.-S., Qu, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241522398 · Cited by 365
Wang, Y., Lee, A. T. C., Ma, J. Z. I., Wang, J., Ren, J., Yang, Y., Tantoso, E., Li, K.-B., Ooi, L. L. P. J., Tan, P., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707629200 · Cited by 363
Tobe, T., Uchino, J., Endo, Y., Oto, M., Okamoto, E., Kojiro, M., Shikata, T., Tanikawa, K., Tsuzuki, T., Mizumoto, R., et al. (1994) · Cancer · doi:10.1002/1097-0142(19941115)74:10<2772::aid-cncr2820741006>3.0.co;2-v · Cited by 335
Ito, Y., Sasaki, Y., Horimoto, M., Wada, S., Tanaka, Y., Kasahara, A., Ueki, T., Hirano, T., Yamamoto, H., Fujimoto, J., et al. (1998) · Hepatology · doi:10.1002/hep.510270409 · Cited by 334
Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma
Campbell, J. S., Hughes, S. D., Gilbertson, D. G., Palmer, T. E., Holdren, M. S., Haran, A. C., Odell, M. M., Bauer, R. L., Ren, H.-P., Haugen, H. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409722102 · Cited by 333
MicroRNAs 221 and 222 Bypass Quiescence and Compromise Cell Survival
Medina, R., Zaidi, S. K., Liu, C.-G., Stein, J. L., vanWijnen, A. J., Croce, C. M., & Stein, G. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6754 · Cited by 308
Self-citation伊藤, 善. (1998) · doi:10.11501/3155565 · Cited by 300
Higashitsuji, H., Itoh, K., Nagao, T., Dawson, S., Nonoguchi, K., Kido, T., Mayer, R. J., Arii, S., & Fujita, J. (2000) · Nature Medicine · doi:10.1038/71600 · Cited by 299
Comprehensive allelotyping of human hepatocellular carcinoma
Nagai, H., Pineau, P., Tiollais, P., Buendia, M. A., & Dejean, A. (1997) · Oncogene · doi:10.1038/sj.onc.1201136 · Cited by 274
MYCN regulates oncogenic MicroRNAs in neuroblastoma
Schulte, J. H., Horn, S., Otto, T., Samans, B., Heukamp, L. C., Eilers, U., Krause, M., Astrahantseff, K., Klein‐Hitpass, L., Buettner, R., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23153 · Cited by 267
Iizuka, N., Oka, M., Yamada‐Okabe, H., Mori, N., Tamesa, T., Okada, T., Takemoto, N., Tangoku, A., Hamada, K., Nakayama, H., et al. (2002) · PubMed · Cited by 265
The MET receptor tyrosine kinase in invasion and metastasis
Benvenuti, S., & Comoglio, P. M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21183 · Cited by 253
Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma
Rebouissou, S., Bioulac-Sage, P., & Zucman-Rossi, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.10.003 · Cited by 252
Expression and Role of Bcl–Xl in Human Hepatocellular Carcinomas
Takehara, T., Liu, X., Fujimoto, J., Friedman, S. L., & Takahashi, H. (2001) · Hepatology · doi:10.1053/jhep.2001.25387 · Cited by 246
Survival and apoptosis: a dysregulated balance in liver cancer
Fabregat, I., Roncero, C., & Fernández, M. (2007) · Liver International · doi:10.1111/j.1478-3231.2006.01409.x · Cited by 225
Cyclin G Recruits PP2A to Dephosphorylate Mdm2
Okamoto, K., Li, H., Jensen, M. R., Zhang, T., Taya, Y., Thorgeirsson, S. S., & Prives, C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00504-x · Cited by 215 · cited 1×
“Later, it was found that cyclin G1 can exert a negative regulation on p53 tumour suppressor gene by recruiting the B subunit of PP2A phosphatase to dephosphorilate and activate Mdm-2, thus leading to p53 degradation [105, 106].”
BackgroundThe role of p53 and pRB in apoptosis and cancer
Hickman, E. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00265-9 · Cited by 214
Kim, S., Lee, U. J., Kim, M. N., Lee, E.-J., Kim, J. Y., Lee, M. Y., Choung, S., Kim, Y. J., & Choi, Y.-C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800186200 · Cited by 210
Overexpression of VEGF and Angiopoietin 2: A Key to High Vascularity of Hepatocellular Carcinoma?
Moon, W. S., Rhyu, K. H., Kang, M. J., Lee, D. G., Yu, H. C., Yeum, J. H., Koh, G. Y., & Tarnawski, A. S. (2003) · Modern Pathology · doi:10.1097/01.mp.0000071841.17900.69 · Cited by 210
Rosmorduc, O., Wendum, D., Corpechot, C., Galy, B., Sebbagh, N., Raleigh, J., Housset, C., & Poupon, R. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65209-1 · Cited by 205
p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma
Matsuda, Y., Ichida, T., Matsuzawa, J., Sugimura, K., & Asakura, H. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70137-x · Cited by 202
Wang, S. M., Ooi, L. L. P. J., & Hui, K. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2236 · Cited by 198
Immunohistochemical detection of bcl-2 protein in normal and pathological human liver.
Charlotte, F., L’Herminé, A. C., Martin, N., Geleyn, Y., Nollet, M., Gaulard, P., & Zafrani, E. (1994) · PubMed Central · Cited by 188
Ganten, T. M., Koschny, R., Haas, T. L., Sykora, J., Li-Weber, M., Herzer, K., & Walczak, H. (2005) · Hepatology · doi:10.1002/hep.20807 · Cited by 170
Fischer, A. N. M., Fuchs, E., Mikula, M., Huber, H., Beug, H., & Mikulits, W. (2006) · Oncogene · doi:10.1038/sj.onc.1210121 · Cited by 162
Ito, Y., Matsuura, N., Sakon, M., Miyoshi, E., Noda, K., Takeda, T., Umeshita, K., Nagano, H., Nakamori, S., Dono, K., et al. (1999) · Hepatology · doi:10.1002/hep.510300114 · Cited by 162
Huang, Y.-S., Dai, Y., Yu, X.-F., Bao, S.-Y., Yin, Y., Tang, M., & Hu, C. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05223.x · Cited by 158
Woo, H. G., Park, E. S., Cheon, J. H., Kim, J. H., Lee, J.-S., Park, B. J., Kim, W., Park, S. C., Chung, Y. J., Kim, B. G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1473 · Cited by 157
Prueitt, R. L., Yi, M., Hudson, R. S., Wallace, T. A., Howe, T. M., Yfantis, H. G., Lee, D. H., Stephens, R. M., Liu, C., Calin, G. A., et al. (2008) · The Prostate · doi:10.1002/pros.20786 · Cited by 157
Self-citationDiaz-Meyer, N., Day, C. D., Khatod, K., Maher, E. R., Cooper, W., Reik, W., Junien, C., Graham, G., Algar, E. M., Kaloustian, V. M. D., et al. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.11.797 · Cited by 150
Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma.
Smith, M. W., Yue, Z. N., Geiss, G. K., Sadovnikova, N. Y., Carter, V. S., Boix, L., Lázaro, C. A., Rosenberg, G. B., Bumgarner, R. E., Fausto, N., et al. (2003) · PubMed · Cited by 148
Schattenberg, J. M., Galle, P. R., & Schuchmann, M. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01324.x · Cited by 145
Schmelzle, T., Mailleux, A. A., Overholtzer, M., Carroll, J. S., Solimini, N. L., Lightcap, E. S., Veiby, O. P., & Brugge, J. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700115104 · Cited by 145
Zauberman, A., Lupo, A., & Oren, M. (1995) · PubMed · Cited by 145
Activation of p53 Tumor Suppressor by Hepatitis C Virus Core Protein
Lu, W. Y., Lo, S., Chen, M., Wu, K.-J., Fung, Y. K., & Ou, J. J. (1999) · Virology · doi:10.1006/viro.1999.9979 · Cited by 140
c-met mRNA overexpression in human hepatocellular carcinoma
Boix, L., Rosa, J. L., Ventura, F., Castells, A., Bruix, J., Rodés, J., & Bartrons, R. (1994) · Hepatology · doi:10.1002/hep.1840190115 · Cited by 140
Boige, V., Laurent‐Puig, P., Fouchet, P., Fléjou, J., Monges, G., Bédossa, P., Bioulac‐Sage, P., Capron, F., Schmitz, A., Olschwang, S., et al. (1997) · PubMed · Cited by 132
Hepatocyte growth factor/scatter factor‐induced intracellular signalling
Stuart, K. A., Riordan, S. M., Lidder, S., Crostella, L., Williams, R. L., & Skouteris, G. G. (2000) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2000.00138.x · Cited by 130
Expression of the C– Met Protooncogene in Human Hepatocellular Carcinoma
Suzuki, K., Hayashi, N., Yamada, Y., Yoshihara, H., Miyamoto, Y., Ito, Y., Ito, T., Katayama, K., Sasaki, Y., Ito, A., et al. (1994) · Hepatology · doi:10.1002/hep.1840200520 · Cited by 125
Molecular-based prediction of early recurrence in hepatocellular carcinoma
Kurokawa, Y., Matoba, R., Takemasa, I., Nagano, H., Dono, K., Nakamori, S., Umeshita, K., Sakon, M., Ueno, N., Oba, S., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.04.031 · Cited by 120
Platelet-derived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer
Stock, P., Monga, D. K., Tan, X., Micsenyi, A., Loizos, N., & Monga, S. P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0720 · Cited by 120
Höpfner, M., Schuppan, D., & Scherübl, H. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1 · Cited by 106
Prognostic significance of Bcl-xL in human hepatocellular carcinoma
Watanabe, J., Kushihata, F., Honda, K., Sugita, A., Tateishi, N., Mominoki, K., Matsuda, S., & Kobayashi, N. (2004) · Surgery · doi:10.1016/j.surg.2003.11.015 · Cited by 103
Skotzko, M. J., Wu, L., Anderson, W. F., Gordon, E. M., & Hall, F. L. (1995) · PubMed · Cited by 102
Cyclin D1 overexpression in hepatocellular carcinoma
Joo, M., Kang, Y. K., Kim, M., Lee, H., & Jang, J. (2001) · Liver International · doi:10.1034/j.1600-0676.2001.021002089.x · Cited by 100
Delpuech, O., Trabut, J., Carnot, F., Feuillard, J., Bréchot, C., & Kremsdorf, D. (2002) · Oncogene · doi:10.1038/sj.onc.1205392 · Cited by 97
Schmitt, M., Horbach, A., Kubitz, R., Frilling, A., & Häussinger, D. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.04.035 · Cited by 95
Weihrauch, M., Benicke, M., Lehnert, G., Wittekind, C., Wrbitzky, R., & Tannapfel, A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1675 · Cited by 77
Reduced Hepatic Tumor Incidence in Cyclin G1–Deficient Mice
Jensen, M. R., Factor, V. M., Fantozzi, A., Helin, K., Huh, C.-G., & Thorgeirsson, S. S. (2003) · Hepatology · doi:10.1053/jhep.2003.50137 · Cited by 75
MicroRNA expression profiling: A molecular tool for defining the phenotype of hepatocellular tumors
Braconi, C., & Patel, T. C. (2008) · Hepatology · doi:10.1002/hep.22326 · Cited by 75
Villanueva, A., Toffanin, S., & Llovet, J. M. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328302c9e9 · Cited by 73
Dhar, D. K., Naora, H., Yamanoi, A., Ono, T., Kohno, H., Otani, H., & Nagasue, N. (2002) · PubMed · Cited by 67
Uematsu, S., Higashi, T., Nouso, K., Kariyama, K., Nakamura, S., Suzuki, M., Nakatsukasa, H., Kobayashi, Y., Hanafusa, T., Tsuji, T., et al. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03726.x · Cited by 67
Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas
Challen, C., Guo, K., Collier, J. D., Cavanagh, D. R., & Bassendine, M. F. (1992) · Journal of Hepatology · doi:10.1016/0168-8278(92)90181-n · Cited by 61
Loss of methylation at chromosome 11p15.5 is common in human adult tumors
Scelfo, R. A., Schwienbacher, C., Veronese, A., Gramantieri, L., Bolondi, L., Querzoli, P., Nenci, I., Calin, G. A., Angioni, A., Barbanti‐Brodano, G., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205336 · Cited by 59
Self-citationSoejima, H., Nakagawachi, T., Wei, Z., Higashimoto, K., Urano, T., Matsukura, S., Kitajima, Y., Takeuchi, M., Nakayama, M., Oshimura, M., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207576 · Cited by 58
Eckel, F., von Delius, S., Mayr, M. F., Dobritz, M., Fend, F., Hosius, C., Schleyer, E., Schulte‐Frohlinde, E., Schmid, R. M., & Lersch, C. (2005) · Oncology · doi:10.1159/000089990 · Cited by 56
Chen, G. G., Lai, P. B. S., Chan, P. K. S., Chak, E. C. W., Yip, J. H. Y., Ho, R. L. K., Leung, B. C. S., & Lau, W. Y. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00182-4 · Cited by 55
The negative role of cyclin G in ATM-dependent p53 activation
Ohtsuka, T., Jensen, M. R., Kim, H. G., Kim, K., & Lee, S. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207693 · Cited by 51
p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis
Matsuda, Y., & Ichida, T. (2006) · Medical Molecular Morphology · doi:10.1007/s00795-006-0339-2 · Cited by 48
Takada, S., & Koike, K. (1989) · PubMed · Cited by 45
Hepatocellular Carcinoma and Markers of Apoptosis (bcl-2, bax, bcl-x): Prognostic Significance
Garcia, E., Lawson, D., Cotsonis, G., & Cohen, C. (2002) · Applied immunohistochemistry & molecular morphology · doi:10.1097/00129039-200209000-00004 · Cited by 44
Salvi, A., Arici, B., Portolani, N., Giulini, S. M., Petro, G. D., & Barlati, S. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.2.451 · Cited by 43
A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma.
Iguchi, H., YOKOTA, M., Fukutomi, M., Uchimura, K., Yonemasu, H., Hachitanda, Y., Nakao, Y., Tanaka, Y., Sumii, T., & Funakoshi, A. (2002) · PubMed · Cited by 31
Kampmeier, J., Behrens, A., Wang, Y., Yee, A. G., Anderson, W. F., Hall, F. L., Gordon, E. M., & McDonnell, P. J. (2000) · Human Gene Therapy · doi:10.1089/10430340050016102 · Cited by 28
Treiber, G., Wex, T., Schleyer, E., Troeger, U., Hosius, C., & Malfertheiner, P. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.10.041 · Cited by 24
Structure and Chromosomal Assignment of the Human Cyclin G Gene
Endo, Y., Fujita, T., Tamura, K., Tsuruga, H., & Nojima, H. (1996) · Genomics · doi:10.1006/geno.1996.0598 · Cited by 23
Lee, K. H., Choi, E. Y., Hyun, M. S., Jang, B. I., Kim, T. N., Lee, H. J., Eun, J. Y., Kim, H. G., Yoon, S. S., Lee, D. S., et al. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9106-6 · Cited by 20
Chromosome Localization and Structure of the Murine Cyclin G1 Gene Promoter Sequence
Jensen, M. R., Factor, V. M., Zimonjic, D. B., Miller, M. J., Keck, C. L., & Thorgeirsson, S. S. (1997) · Genomics · doi:10.1006/geno.1997.4947 · Cited by 10
Ferrero, S., & Ragni, N. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.08.924 · Cited by 8
Cited by
Hou, J., Lin, L., Zhou, W., Wang, Z., Ding, G., Dong, Q., Qin, L., Wu, X., Zheng, Y., Yang, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.001 · Cited by 690
Li, L.-M., Hu, Z.-B., Zhou, Z.-X., Chen, X., Liu, F.-Y., Zhang, J.-F., Shen, H.-B., Zhang, C.-Y., & Zen, K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1001 · Cited by 451
MicroRNAs: Novel regulators in the hallmarks of human cancer
Ruan, K., Fang, X., & Ouyang, G. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.04.031 · Cited by 447
Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Calin, G. A., Grazi, G. L., Pollutri, D., Croce, C. M., Bolondi, L., & Gramantieri, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0145 · Cited by 396
Self-citationHe, X.-X., Chang, Y., Meng, F.-Y., Wang, M.-Y., Xie, Q.-H., Tang, F., Li, P.-Y., Song, Y.-H., & Lin, J.-S. (2012) · Oncogene · doi:10.1038/onc.2011.500 · Cited by 339
Metadata
- Authors
- Gramantieri, L., Fornari, F., Callegari, E., Sabbioni, S., Lanza, G., Croce, C. M., Bolondi, L., & Negrini, M.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2008-12
- Volume
- 12
- Issue
- 6a
- Pages
- 2189-2204
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W2109261002
- Cited by
- 304
- References
- 149
- FWCI
- 5.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.